Meridian Bioscience Profit Margin

The latest profit margin for VIVO is -0.9% as of December 2022. That compares with 19.14% in the prior-year period — down 104.7% year over year. That is below the Healthcare sector average of 13.45%. Investors often review this figure alongside Meridian Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, VIVO's profit margin moved from 19.14% to -0.9% — a 104.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Meridian Bioscience's valuation or profitability profile.

Against Healthcare companies, VIVO currently prints -0.9% for profit margin, while the sector average sits near 13.45%. That is roughly 106.7% below the sector mean. Large gaps often invite a closer look at Meridian Bioscience's growth, margins, and balance sheet.

Profit Margin shows how effectively Meridian Bioscience converts resources into returns. At -0.9%, VIVO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 19.14% in the prior-year period — down 104.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VIVO's profit margin (-0.9%), review year-over-year change from 19.14%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.